why choose us

First received: January 11, 2023

Clinical Trial: Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

Study Status: Completed

Recruit Status: RECRUITING

Condition: Invasive Mammary Carcinoma

Study Type: INTERVENTIONAL


Official Title: Integrating Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT)

Brief Summary: This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e.capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Read more